As of October 28, 2026, Opus Genetics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 21, 2026 (Form 8-K, October 21, 2026).
Sell to companies like Opus Genetics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Opus Genetics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-21. Every row below is cited to the filing it comes from, and this page adds each new change as Opus Genetics, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-21 | Reported | not named in the filing | 8-K, 2026-10-21 |
Selling to them or working with them? See who runs Opus Genetics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Opus Genetics, Inc. and the records around it.
Opus Genetics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
- Balyasny Asset Management L.P. also filed stake reports on 31 other companies: Beyond Air, Inc. (Aug 2026), Camp4 Therapeutics Corp. (Aug 2026), CELLECTAR BIOSCIENCES, INC. (Aug 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026), Kardigan, Inc. (Oct 2026)
Watch Opus Genetics, Inc.
Get an email when Opus Genetics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Opus Genetics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Opus Genetics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Opus Genetics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
New leaders reset buying decisions — get the Full Report on Opus Genetics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Opus Genetics, Inc., with the record behind each one.
Find candidates like senior executive at Opus Genetics, Inc.Every change, in the filing's words
Reported
Opus Genetics, Inc. (the "Company") and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the Company's Chief Scientific and Development Officer, effective as of October 19, 2026 (the "Separation Date").
Tools for this story
Each opens in a new tab, filled in for Opus Genetics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.